Ogivri (Trastuzumab)

Trastuzumab, the active ingredient in Ogivri, is a monoclonal antibody presented as a 440 mg/10 ml solution for intravenous use. It treats HER2‑positive breast cancer in adult patients.

GNH USA supplies Ogivri as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Ogivri is a HER2‑targeted therapy used in the management of cancers that overexpress the HER2 protein. - Early‑stage HER2‑positive breast cancer: improves disease‑free survival when given as part of adjuvant therapy. - Metastatic HER2‑positive breast cancer: prolongs overall survival in combination with chemotherapy. - HER2‑positive gastric or gastro‑oesophageal junction adenocarcinoma: used with chemotherapy in the first‑line setting.

Adverse reactions to Ogivri may range from mild to severe and are monitored throughout treatment.

Common Side Effects: - Fever, chills and rigour - Nausea or vomiting - Fatigue - Diarrhoea - Headache - Infusion‑related erythema

Serious or Rare Side Effects: - Cardiac dysfunction or decreased left‑ventricular ejection fraction - Severe infusion‑related reactions, including anaphylaxis - Pulmonary toxicity (interstitial pneumonitis) - Thromboembolic events - Hepatitis B reactivation - Severe skin reactions such as Stevens‑Johnson syndrome

When administering Ogivri, clinicians should observe several safety measures. - Cardiac monitoring: regular echocardiograms or MUGEE studies   - Pregnancy  :                       test  t t   t   t  ullet   ewline -   ewline -  ullet   \

The        ... ... ... ...  …  ....